Royal Philips (PHG) announced Philips SmartIQ, a breakthrough coronary imaging technology for its Azurion image-guided therapy. Developed in collaboration with leading cardiovascular centers, SmartIQ is designed to address one of the field’s most fundamental challenges: the trade-off between image quality and radiation exposure for patients and clinical staff. It aims to empower clinicians with exceptional image quality, enabling them to see exactly what they need, while it aims to provide reassurance that X-ray dose and contrast levels are optimized.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHG:
- Philips consortium chosen for Region Stockholm hospital-at-home initiative
- Philips shareholders back board slate and renew CEO mandate at 2026 AGM
- Philips reports Q1 adjusted EPS EUR 0.23 vs. EUR 0.25 last year
- Philips backs FY26 comparable sales growth view 3%-4.5%
- Philips Earnings Call Highlights Growth Amid Headwinds
